← Back to Clinical Trials
Recruiting NCT07524023

NCT07524023 Emotional-distress-based Integrated Care Programme in Patients With Stable COPD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07524023
Status Recruiting
Phase
Sponsor University of Zurich
Condition COPD
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2026-03-16
Primary Completion 2026-09-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
EmoD Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2026-03-16 with a primary completion date of 2026-09-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators have developed a new counselling service that focuses on the emotional distress experienced by people living with chronic obstructive pulmonary disease (\*COPD\*). The new programme is led by an advanced practice nursing (\*APN\*) team. Other professionals are involved in the programme, such as medical staff and physiotherapists. The new counselling service lasts three months. Patients will receive ten counselling sessions with a specialized nurse. The overall objective of the study is to assess the feasibility of the newly developed emotional-distress-based integrated care programme.

Eligibility Criteria

Inclusion Criteria: * Patients with a confirmed diagnosis of COPD (GOLD 1-4) and existing lung function in the past 12 months * Age ≥ 18 * Outpatient treatment on the pneumology clinic of the university hospital Zurich. Last consultation within the past 12 months Exclusion Criteria: * Significant changes in symptoms over the past 3 months that exceeded the everyday fluctuations and required intensification of treatment (moderate, severe exacerbations or pneumonia) and no COPD-related hospitalisation in the past 3 months * Cognitive impairment (dementia, delirium) * Unstable psychiatric situation, i.e., current psychiatric treatment due to personality disorder, schizophrenia, drug use, suicidal tendencies. No exclusion for nicotine and alcohol abuse, anxiety, and depression * Not speaking or reading German * Intervention via telephone or video call not possible * Lung transplant (recipient or candidate)

Contact & Investigator

Central Contact

Gabriela Schmid-Mohler, PD, PhD

✉ gabriela.schmid@usz.ch

📞 +41 44 255 20 03

Frequently Asked Questions

Who can join the NCT07524023 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07524023 currently recruiting?

Yes, NCT07524023 is actively recruiting participants. Contact the research team at gabriela.schmid@usz.ch for enrollment information.

Where is the NCT07524023 trial being conducted?

This trial is being conducted at Zurich, Switzerland.

Who is sponsoring the NCT07524023 clinical trial?

NCT07524023 is sponsored by University of Zurich. The trial plans to enroll 15 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology